TWST Twist Bioscience 10-K 2026-09-30 section summaries

An AI model summarized each section of the report on its own; the summary was written from these. They are longer and less edited than the summary, and the filing on SEC is the authority.

Item 1, Business

Business overview and FY2026 revenue

Twist reported FY2026 revenue of $459.4 million and served approximately 4,100 customers. Revenue by end market and channel was:

FY2026 revenue category Revenue
Diagnostics $164.3 million
Therapeutics $162.3 million
Academic research and government $56.6 million
Global supply partners $52.0 million
Industry and applied markets $24.2 million

Beginning in FY2026, Twist grouped synthetic biology products and antibody-discovery biopharma services as DNA Synthesis and Protein Solutions, reflecting customers’ increasing use of the offerings together. It renamed its NGS tools group NGS Applications.

Platform, markets and growth strategy

Twist’s platform synthesizes DNA directly on silicon chips, producing more than 1 million oligonucleotides of up to 500 bases per chip while using 99.8% less chemicals than plate-based synthesis. The company reports error rates of 1:7,500 nucleotides for gene fragments and 1:3,000 for oligonucleotides. Its manufacturing capabilities include clonal genes up to 7,000 base pairs, non-clonal genes up to 5,000 base pairs, and oligo pools ranging from hundreds to more than one million oligos. The company positions its combination of silicon, software, automation and commercial infrastructure as a way to improve quality, throughput, speed and cost.

Twist estimates its combined 2030 serviceable addressable markets (SAM) at more than $13 billion: approximately $6 billion for NGS Applications and more than $7 billion for DNA Synthesis and Protein Solutions. The related total addressable markets are estimated at more than $90 billion and approximately $18 billion, respectively. NGS SAM includes oncology diagnostics ($3.6 billion), academic research ($800 million), microarrays ($500 million), rare and inherited disease ($400 million), and biotech/pharma R&D ($400 million). DNA Synthesis and Protein Solutions SAM includes antibody discovery ($2.5 billion), DNA synthesis ($2.0 billion), protein expression ($1.6 billion), and nucleic acid therapeutics ($1.0 billion). As of May 2026, Twist estimated that $1 billion of the latter SAM was AI-enabled drug discovery, split evenly between antibody discovery and protein expression. These are company estimates based partly on third-party information and assumptions.

Demand from AI-enabled drug-discovery customers grew substantially in FY2026. These customers computationally design candidate antibodies or proteins and use Twist to build, test and characterize them and generate data, positioning Twist as a protein and data partner as well as a DNA supplier. In February 2026, Twist entered a co-exclusive license to Invenra’s B-Body bispecific antibody discovery platform and acquired a minority equity interest.

NGS products include sample-preparation products, target-enrichment panels and library-preparation kits for sequencing platforms. Falling sequencing costs may support wider use in liquid biopsy, molecular residual disease (MRD), therapy selection, population-scale, spatial and single-cell sequencing. Twist’s growing exposure to commercial diagnostics customers creates opportunity as their demand scales, but also ties growth to adoption in those markets. Strategy includes adding products and volume using existing infrastructure, expanding protein and therapeutic-discovery capabilities, developing nucleic-acid-therapeutics products, automating operations and extending global reach through direct, digital and partner channels. Expected utilization and unit-economics benefits are strategic aims, not reported results.

Operations, workforce and competition

Twist sells through direct sales, commercial consultants, e-commerce, distributors and OEM partners. Its platform supports product design and ordering, real-time quotes and order tracking. It manufactures substantially all products in South San Francisco, California, and Wilsonville, Oregon; Wilsonville is the primary DNA Synthesis and Protein Solutions site and South San Francisco the primary NGS Applications site. Gene synthesis operates 24/7/365, and automated pooled-DNA production can produce many millions of oligos per day. Some sub-assemblies are outsourced.

As of September 30, 2026, Twist had 1,080 employees: 431 in operations and manufacturing, 321 in marketing, sales and customer support, 198 in general and administration, and 130 in R&D, plus 20 dedicated commercial consultants. No employees were union-represented. The company owned or exclusively in-licensed over 200 issued or allowed patents and had more than 230 pending patent applications worldwide. Some components and raw materials have only one supplier; contingency plans, longer-term supply contracts and supplier qualification are used to mitigate continuity risks.

The company competes in markets characterized by price pressure, technological change, turnaround-time expectations and manufacturing-yield challenges. It cites quality, accuracy, product breadth, speed, price, throughput, scale, innovation and technical support as competitive factors; competitors include Integrated DNA Technologies (Danaher), GenScript, Agilent, Roche, Illumina and WuXi Biologics.

Regulatory exposure

Most products are marketed as research-use-only (RUO), but regulatory status can depend on promotion and customer support as well as labeling. If authorities determine that RUO products are intended for diagnostic use requiring clearance or approval, Twist could be adversely affected, including when a customer uses a product clinically without Twist’s consent. Twist’s limited EU Precision Dx catalog is CE-marked and IVDR-compliant. The EU IVDR imposes requirements including clinical evaluation, quality systems and post-market surveillance; full enforcement is expected by December 2029. Twist is exposed both as an IVD manufacturer and as a supplier to customers selling IVDs in Europe.

In the United States, a federal court vacated the FDA’s 2024 Laboratory Developed Tests Final Rule in full on March 31, 2025; FDA did not appeal and issued a rule effective September 19, 2025 reverting to the prior regulatory text. Legislative efforts, including the Enhancing CLIA Act of 2026, could change the environment for customers’ use of Twist products in laboratory-developed tests. FDA’s Quality Management System Regulation began incorporating ISO 13485:2016 by reference on February 2, 2026; Twist maintains ISO 13485 certification and completed its latest surveillance audit in August 2026.

Twist says its biosecurity practices meet or exceed the OSTP Framework for nucleic-acid synthesis screening, effective April 2025, and it has publicly attested to compliance. The Framework requires covered U.S.-funded researchers and institutions to purchase synthetic nucleic acids from providers making such attestations; Twist must update its attestation within 72 hours if its compliance status changes. Executive Order 14292 in May 2025 directed revision or replacement of the Framework and development of a screening strategy for non-federally funded settings, while pending legislation could establish technical standards for providers. Other exposures include possible export-license requirements for certain sequences and synthetic controls, an expected U.S. export control for DNA writers, and potential future licensing if Twist handles materials covered by the Federal Select Agent Program.

Item 1A, Risk Factors

Financial condition and funding

Twist has incurred net losses every year since inception and expects continued losses and negative free cash flow in the near term. It cautions that revenue growth may not continue and that revenue shortfalls could disproportionately hurt results because a significant portion of operating expenses is relatively fixed.

Net loss / accumulated deficit Amount
FY2026 net loss $130.2M
FY2025 net loss $77.7M
FY2024 net loss $208.7M
Accumulated deficit at September 30, 2026 $1.4498B

In August 2026, Twist sold 3,593,750 common shares at $96.00 per share, generating approximately $327.7M in net proceeds. Under its $200.0M at-the-market program, it had sold 748,909 shares for approximately $97.1M net through September 30, 2026, with approximately $100.0M remaining available. Cash, cash equivalents, short-term investments, and financing proceeds are expected to fund planned expenses, capital expenditures, and other contractual obligations for at least 12 months. Changing needs could require additional financing; equity issuance could dilute shareholders, debt could add covenants and repayment obligations, and unavailable or unfavorable financing could force delays or cuts to manufacturing, R&D, sales, or other activities.

Demand, customers, and competition

Twist’s revenue is substantially derived from products and services based on its silicon-chip DNA synthesis platform. Results depend on sustaining the platform’s performance and cost advantages, developing DNA Synthesis and Protein Solutions and NGS Applications, and diversifying. Established competitors may have stronger brands, intellectual property, resources, manufacturing experience, and distribution, while competing products or lower prices could erode share and margins.

Demand is difficult to predict: customers generally have no long-term minimum-purchase commitments and may reduce or stop orders with little notice. Customer spending depends on research budgets, grants and federal funding, capital-market access, economic conditions, and technology adoption; Twist has experienced order cancellations it believes were related to customer funding concerns. A significant portion of NGS Applications revenue is tied to liquid-biopsy assay developers, whose commercialization, adoption, reimbursement, and decisions to insource sample preparation are outside Twist’s control.

Orders from customers using AI and computational methods for therapeutic discovery grew substantially and became a larger share of DNA Synthesis and Protein Solutions revenue in FY2026. This is an important growth opportunity, but demand is concentrated among a limited number of customers and may recede if customers build internal capabilities, face funding constraints, switch suppliers, or AI approaches fail to improve drug-development outcomes. Orders generally have little long-term contractual protection. Customers could also attribute model or therapeutic-program failures to Twist’s materials or data, creating legal and reputational exposure.

Capacity, supply, and operating continuity

Twist’s capacity investments carry risks of either shortages or excess and obsolete inventory. Protein Solutions requires specialized infrastructure, staff, and third-party partners; investments made ahead of anticipated demand may not earn expected returns. A critical DNA-synthesis component comes from a single supplier. Although Twist maintains reserves and alternatives exist, its process is designed around the incumbent component, so a switch could require redesign and lengthy qualification, raise costs, reduce yields, or delay production.

Substantially all products and multiple sub-assemblies are manufactured at two U.S. facilities: Wilsonville, Oregon, and South San Francisco, California. DNA Synthesis and Protein Solutions and Express are concentrated in Wilsonville; a significant portion of NGS products is made in South San Francisco. A disruption at either site could constrain supply, and transferring production elsewhere would likely be costly and time-consuming. Facility risks include earthquakes, wildfire, extreme heat, severe weather, power and communications outages, and public-health or political events. Third-party carriers, suppliers, and mouse vivariums used for in-vivo antibody discovery also create continuity risks.

Centralized IT systems support production, orders, inventory, shipping, and financial records. Cyberattacks, outages, system migrations, or failures at Twist or its partners could interrupt fulfillment, expose data, cause response and litigation costs, and damage customer relationships. Twist reported no material security breach to its knowledge to date, but cannot assure its defenses or insurance will cover future incidents. IT, automation, cybersecurity, analytics, and AI/ML investments also require resources before benefits may be realized.

Regulation, biosecurity, and international exposure

Synthetic nucleic-acid screening cannot eliminate risks of misuse or noncompliance. Executive Order 14292, issued in May 2025, directed changes to the federal screening framework and development of screening strategies for non-federally funded settings. New requirements could increase costs, slow turnaround, or restrict orders, though qualifying standards could benefit compliant providers. Federal research funding changes and restrictions—including certain research restrictions under the order—could also reduce customer demand.

Twist sells U.S. in-vitro diagnostic products as “Research Use Only.” If the FDA considers marketing or customer use to indicate clinical intent, it could require clearance or approval or impose restrictions. A 2024 FDA rule intended to broadly regulate laboratory-developed tests was vacated in full in March 2025, and the FDA restored prior regulatory text effective September 19, 2025; future regulation remains possible. EU IVDR compliance entails quality-system and post-market-surveillance costs. Clinical testing or clinical use of results could also trigger CLIA obligations. Privacy laws, including CCPA/CPRA and GDPR, impose evolving obligations; California requirements include phased cybersecurity audit certifications beginning in 2028 and certain consumer-risk assessments from January 1, 2026.

International revenue Share of revenue
FY2026 41%
FY2025 42%
FY2024 40%

International expansion adds exposure to tariffs, currency movements, collection and delivery challenges, political instability, IP enforcement, and foreign-law compliance. Tariffs may increase input costs that Twist may be unable to pass on. Foreign dealings also increase FCPA and UK anti-bribery exposure; export controls and sanctions can impede operations. The company identifies possible Section 382 limits on pre-change net operating losses if further ownership changes occur, including through equity issuance.

People, intellectual property, and shareholder risks

Execution depends on CEO Dr. Emily Leproust and scarce scientific and engineering talent, particularly in the competitive San Francisco Bay Area. Twist owned or exclusively in-licensed over 200 issued or allowed patents and had more than 230 pending applications as of September 30, 2026, but patent coverage and foreign enforcement are uncertain. Trade-secret leakage, infringement claims, ownership disputes, costly litigation, unfavorable licensing terms, or loss of licensed rights could delay or block products, require royalties or redesign, and impair competitiveness.

The May 2025 spinout of DNA data-storage activities to Atlas (now AtlasBase) supports focus on core businesses but reduces diversification; returns depend on Atlas’s development and commercialization. Twist retains an equity interest and potential milestone payments and royalties. Its February 2026 license and equity investment with Invenra, and potential future transactions, could consume cash, add debt, dilute shareholders, create integration costs, or fail to deliver expected benefits.

Internal controls were assessed as effective at September 30, 2025 and 2026, but future weaknesses could undermine reporting and investor confidence. Twist has never paid dividends and does not expect to do so in the foreseeable future. Equity sales, equity-plan awards, short-selling activity, volatile results, and securities litigation may pressure the share price; governance and exclusive-forum provisions may limit stockholder actions or takeover opportunities.

Item 1C, Cybersecurity

Cybersecurity Risk Management and Oversight

TWST reports no known cybersecurity threats or prior incidents that have materially affected its strategy, operations, or financial condition. However, it cautions that ongoing threats, if realized, could reasonably be expected to have a material effect on the company.

The company’s cybersecurity program is based on ISO 27001 controls and the NIST Cybersecurity Framework 2.0. TWST maintains ISO 27001:2022 certification and uses independent audits, third-party red-team penetration testing, vulnerability management, employee training, and security-risk assessments of key vendors. Cybersecurity risk management is integrated with enterprise risk management.

The IBT Security team, led by the CIO, maintains the incident response plan, which covers detection through recovery. The team coordinates response with IT, Legal, Finance, and Communications, and conducts tabletop exercises. The CIO has 15 years of IT-management experience.

The Board’s Audit and Risk Committee has primary oversight. The CIO reports to the Committee quarterly on threats, cybersecurity initiatives and investment, assessments, awareness testing, and incidents; the full Board receives an annual program review. Escalation of incidents to management and the Committee depends on severity, and external advisers may be engaged as appropriate.

TWST maintains cybersecurity insurance but warns that coverage may not extend to all claims or losses arising from breaches or cyberattacks.

Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations

FY2026 performance and operating results

Revenue grew 22% year over year, with higher sales across product categories and customer industries, more customers, and increased demand from global supply partners. Fixed-cost leverage helped gross margin expand 1.7 percentage points. However, higher SG&A and litigation costs more than offset gross-profit growth, widening the operating loss. Net loss also increased; FY2025 included a gain on the sale of the DNA data-storage business that did not recur in FY2026.

FY ended September 30 FY2026 FY2025
Revenue $459.433M $376.572M
Cost of revenue $218.632M $185.570M
Gross profit $240.801M $191.002M
Gross margin 52.4% 50.7%
Selling, general and administrative expense $301.215M $246.976M
Research and development expense $71.836M $80.285M
Net litigation settlement costs $7.205M —
Operating loss $(139.455)M $(136.259)M
Net loss $(130.2)M $(77.7)M
Interest income $8.803M $11.364M

Cost of revenue increased 18%, mainly from $26.3M of higher material costs on increased volume, plus $4.2M of personnel costs and $1.6M of depreciation and amortization. A significant portion of production costs is fixed, supporting margin gains as revenue grows; product mix, launches, and capacity or automation investments ahead of demand may offset that leverage. SG&A rose 22%, including increases of $28.5M in personnel costs—primarily commercial-team additions—$8.5M in outside services, $7.9M in stock-based compensation, and $6.7M in IT services. The company expects further selling-cost growth to support commercial coverage, international expansion, marketing, and customer growth. R&D declined largely following the FY2025 sale of the DNA data-storage business. FY2026 litigation settlement costs, net of expected insurance recoveries, primarily related to securities class and derivative actions.

Revenue mix and operating metrics

The company regrouped several offerings—including synthetic genes, oligo pools, DNA libraries, and antibody-discovery biopharma services—into DNA Synthesis and Protein Solutions for FY2026, and renamed NGS tools as NGS Applications. Customer-industry categories were also updated, so comparisons reflect the reported groupings.

Revenue category FY2026 FY2025
Product categories
DNA Synthesis and Protein Solutions $221.892M $168.468M
NGS Applications $237.541M $208.104M
Customer industries
Therapeutics $162.297M $110.544M
Diagnostics $164.311M $145.411M
Industry and applied $24.219M $24.508M
Academic research and government $56.598M $49.893M
Global supply partners $52.008M $46.216M
Geography
Americas $278.763M $225.580M
EMEA $147.992M $124.240M
APAC $32.678M $26.752M
Revenue recognition timing
Recognized over time $58.670M $26.537M
Recognized at a point in time $400.763M $350.035M

AI-enabled drug-discovery demand grew substantially and materially contributed to DNA Synthesis and Protein Solutions growth; the company expects further growth in FY2027. This emerging use case has a higher service mix. NGS Applications revenue is increasingly concentrated among large commercial diagnostics customers, exposing results to their demand and to reimbursement, regulatory, and commercial developments. Academic and government orders vary with appropriations and grant timing. Lower-priced offerings have increased unit volumes but reduced average prices.

Operating metric FY2026 FY2025
Genes shipped ~1.341M (+43%) 938,000
Customers 4,100 (+8%) 3,800

The company cautions that gene length, complexity, and price vary, as does customer size, so shipments and customer counts do not move proportionately with revenue.

Cash flows, funding, and financial position

Operating cash use improved despite the larger net loss, in part because of noncash expenses. FY2026 noncash adjustments were $96.6M, mainly $69.9M of stock-based compensation and $26.5M of depreciation and amortization. Net working-capital outflows were $7.8M: $21.8M from prepaid/current assets, $18.1M from inventory, and $13.8M from receivables, partly offset by increases in accrued expenses and other liabilities ($26.3M), accounts payable ($13.9M), and accrued compensation ($7.1M). FY2025 noncash adjustments were $42.6M and included the $48.8M gain on sale of the business.

Cash flow item FY2026 FY2025
Operating cash used $41.431M $47.628M
Property and equipment purchases $47.6M $28.0M
Investing cash used $53.088M $24.762M
Financing cash provided $446.678M $28.540M

FY2026 financing cash provided included $424.8M of net proceeds from the August public offering and ATM sales, $17.6M from option exercises, and $4.3M from the employee stock purchase plan. FY2025 financing included $15.0M from XOMA, $9.3M from option exercises, and $4.2M from the employee stock purchase plan. FY2026 investing cash use also included $7.0M of IP purchases—$5.0M in cash for the Invenra license and $2.0M for other licenses—partly offset by $1.4M of net investment maturities. FY2025 investing cash use included $2.5M of proceeds from the data-storage business sale.

Balance-sheet item at September 30 FY2026 FY2025
Cash and cash equivalents $533.992M $183.049M
Short-term investments $47.915M $49.385M
Total assets $1,121.808M $641.861M
Total stockholders’ equity $888.016M $472.958M
Accumulated deficit $1,449.780M $1,319.578M

In August 2026, Twist sold 3,593,750 common shares at $96.00 per share for $327.7M net proceeds after $17.3M of discounts, commissions, and expenses. Through September 30, it also sold 748,909 shares under its ATM program for $97.1M net; $100.0M of ATM capacity remained. The agreement permits up to $200.0M of gross sales and charges commissions of up to 3%. Cash held by foreign subsidiaries was $6.6M.

Management believes cash, cash equivalents, and short-term investments can fund operations, capital expenditures, and identified material cash needs for at least 12 months from the filing date, based on its operating plan and excluding uncompleted financing, including future ATM sales. Longer-term needs may increase with growth, R&D, facilities, commercial expansion, IP litigation, acquisitions, or investments. Future financing may be unavailable or could bring dilution, covenants, or repayment obligations.

Investment plans, commitments, and estimates

The company expects approximately $150M of capital expenditures over the next two fiscal years to expand manufacturing capacity at existing facilities, intended to support more than $1.0B of annual revenue. Capital-expenditure commitments were $18.4M at September 30, 2026, substantially all expected to be paid within 12 months; anticipated landlord tenant-improvement allowances total $34.8M.

In February 2026, the company entered a co-exclusive license for Invenra’s B-Body bispecific-antibody discovery platform and acquired a 6.24% fully diluted equity interest. Total consideration was $33.8M: $20.0M for the license, including $5.0M in cash with the balance settled in common stock, and a $13.8M equity investment settled in common stock. Twist also owes royalties on gross revenue from third-party licenses.

The Atlas DNA-data-storage asset transfer consideration included 73.0M Series Seed-1 preferred shares, $2.5M upfront cash, $2.0M in promissory notes, milestones of up to $75.0M, and sales-based royalties. Uncertain milestone and royalty receipts are excluded from liquidity estimates. XOMA received $15.0M in October 2024 for the right to half of future potential milestone and royalty payments from certain customer agreements; Twist’s obligation is to remit a share of receipts, rather than fund them from existing cash.

Undiscounted operating lease obligations were $149.9M, with $8.5M due within 12 months. The South San Francisco headquarters lease was extended through June 30, 2037, and expanded by approximately 66,000 square feet. Rent on existing premises is abated through October 2027. The added space is expected to commence in January 2027, is excluded from the stated lease obligations, and carries approximately $42.7M of base rent through June 2037, with payments beginning in FY2028 after abatement. A Carlsbad lease is expected to commence in April 2027, with approximately $2.2M of base rent over five years.

FY2026 revenue recognized over time for antibody-discovery, optimization, and characterization services was $58.7M, or 13% of revenue. Recognition depends on costs incurred relative to estimated total costs; early-program estimates are more uncertain and can require cumulative catch-up adjustments, though none were material in FY2026. PRSU expense likewise depends on whether multi-year revenue, gross-margin, and profitability targets are considered probable, with changes potentially causing cumulative reversals or catch-up charges. No long-lived-asset impairment indicators or charges were recorded in FY2026 or FY2025; FY2024 included a $44.9M antibody-discovery-services impairment. Private-company equity investments, including Atlas and Invenra, had a combined carrying value of $68.1M, versus $54.3M a year earlier. These investments generally are not remeasured absent observable transactions, so value changes may be recognized in a single period and be material; no adjustments or impairments were recorded in FY2026, compared with impairments of $1.1M in FY2025 and $2.2M in FY2024.

Item 7A, Quantitative and Qualitative Disclosures About Market Risk

Item 7A — Quantitative and Qualitative Disclosures About Market Risk

Measure September 30, 2026 September 30, 2025
Cash, cash equivalents and short-term investments $581.9M $232.4M

The increase in cash and short-term investments was primarily due to net proceeds from the August 2026 underwritten public offering and at-the-market sales. The portfolio consists mainly of money market funds and investment-grade, short-duration fixed-income securities, and is managed to preserve capital while generating income. A hypothetical 10% relative change in interest rates would not materially affect portfolio fair value; a 100-basis-point rate decrease would reduce annual interest income by approximately $5.2M based on September 30, 2026 balances.

Most transactions are denominated in U.S. dollars. Other-currency exposure is primarily to the euro, Chinese yuan, Japanese yen and British pound. The company does not hedge foreign-currency exposure and does not use derivatives for speculative or trading purposes. A hypothetical 10% change in the U.S. dollar against those currencies would not materially affect the consolidated financial statements.

Preferred-stock investments in private companies, including Invenra and Atlas, had an aggregate carrying value of $68.1M at September 30, 2026. These investments are measured at cost less impairment, adjusted for observable price changes. Deterioration in investees’ financial condition or in comparable-company valuations could result in impairment or other losses in earnings.

Item 8, Financial Statements and Supplementary Data

Business and revenue

Twist’s silicon-based synthetic-DNA platform serves therapeutics, diagnostics, industrial and agricultural, academic, and government customers. It sells DNA Synthesis and Protein Solutions and NGS Applications products and services, including synthetic genes, oligo pools, sequencing tools, sample preparation, synthetic RNA, and antibody-discovery offerings. The company has one operating and reportable segment; its CEO evaluates results and allocates resources on a consolidated basis.

Consolidated results ($M, except per-share data) FY2026 FY2025 FY2024
Revenue 459.433 376.572 312.974
Cost of revenue 218.632 185.570 —
Gross profit 240.801 191.002 —
Operating expenses 380.256 327.261 —
Operating loss (139.455) (136.259) (220.831)
Net loss attributable to common stockholders (130.202) (77.670) (208.726)
Loss per share, basic and diluted $(2.08) $(1.30) $(3.60)
Weighted-average shares (M) 62.615 59.808 58.016

Revenue increased 22.0% in FY2026, following 20.3% growth in FY2025. Revenue recognized over time, primarily for antibody-discovery services, grew much faster than product revenue. FY2025 net loss benefited from a $48.847M gain on sale of the DNA data-storage business; FY2026 operating expenses included $7.205M of litigation settlement costs, net of recoveries. FY2024 included a $44.930M long-lived-asset impairment. Interest income declined to $8.803M in FY2026 from $11.364M in FY2025 and $15.344M in FY2024.

Revenue breakdowns

Revenue category ($M) FY2026 FY2025
Point-in-time revenue, primarily product sales 400.8 350.0
Over-time revenue, primarily antibody-discovery services 58.7 26.5
DNA Synthesis and Protein Solutions 221.89 168.47
NGS Applications 237.54 208.10
Therapeutics 162.30 110.54
Diagnostics 164.31 145.41
Industry and applied 24.22 24.51
Academic research and government 56.60 49.89
Global supply partners 52.01 46.22
Americas 278.76 225.58
EMEA 147.99 124.24
APAC 32.68 26.75

Over-time revenue rose 121.5%, versus 14.5% growth in point-in-time revenue; therapeutics was the fastest-growing listed customer group, while industry and applied declined. Revenue categories were recast in FY2026 to reflect customers’ combined use of offerings. The United States generated 59% of FY2026 revenue; no individual customer accounted for 10% or more of revenue in FY2024–FY2026.

Financial position, cash flow, and funding

Balance sheet ($M) Sep. 30, 2026 Sep. 30, 2025
Total assets 1,121.808 641.861
Total stockholders’ equity 888.016 472.958
Goodwill 82.195 82.195
Intangible assets, net, excluding goodwill 34.164 13.425
Cash and cash equivalents 533.992 183.049
Short-term investments 47.915 49.385
Cash flow ($M) FY2026 FY2025
Net cash used in operating activities (41.431) (47.628)
Property and equipment purchases (capex proxy) (47.583) (28.004)
Purchases of intangible assets (6.950) —

Cash, cash equivalents, and short-term investments totaled $581.91M at FY2026 year-end. Operating cash use improved, but capital investment increased. Net financing cash provided was $446.678M, largely reflecting $424.830M of net public-offering proceeds. Common shares outstanding rose from 60.632M at FY2025 year-end to 67.813M at FY2026 year-end. The August 2026 follow-on offering generated $327.7M net; ATM sales generated $97.1M net, with $100.0M of capacity remaining. Management expects cash, cash equivalents, and short-term investments to fund operations for at least one year from issuance of the financial statements.

Stock-based compensation expense was $69.856M in FY2026, versus $64.459M in FY2025 and $50.925M in FY2024. Year-end nonvested awards included 2.363M RSUs and 2.366M performance-based RSUs; unrecognized compensation cost was $80.3M for RSUs and $28.6M for performance-based RSUs. Performance awards can vest at 0%–150% of granted units. Separately, 0.552M options remained outstanding and exercisable, with $85.121M aggregate intrinsic value. Potentially dilutive securities were excluded from diluted loss per share as antidilutive; excluded shares totaled 5.307M in FY2026, including 0.552M options, 4.729M unvested RSUs/PSUs, and 0.026M ESPP shares.

Investments, commitments, and risks

FY2026 included a $20.0M seven-year co-exclusive license to Invenra’s B-Body antibody-discovery platform, paid with $5.0M cash and $15.0M in company shares. The license is amortized over 11 years. Twist’s private-company investments were $68.1M, including $67.6M related-party investments; total assets and maximum exposure to unconsolidated VIEs were $70.1M, with no future funding commitments. Invenra is a related-party VIE that Twist does not consolidate.

Remaining performance obligations were $21.6M, of which $15.9M was expected to be recognized over the next 12 months; substantially all product orders are excluded because their original duration is one year or less. The company monetized certain future customer-contract milestones and royalties through an arrangement accounted for as debt; estimated aggregate payments to XOMA did not exceed $15.0M.

The South San Francisco lease expansion extends the overall lease to June 2037. The two additional floors carry approximately $42.7M of undiscounted rent through June 2037, before approximately $24.9M of allowances, and were not yet included in reported lease liabilities at year-end. Reported operating lease liabilities were $94.985M. Litigation-related balances increased: a securities class-action settlement in principle was approximately $17.1M, subject to court approval, with insurers expected to fund most of it; a $16.7M insurance receivable was recorded. Twist also relies on a limited number of suppliers, sometimes a single supplier, and holds cash at two financial institutions in amounts that may exceed federally insured limits.

The company has incurred operating losses since inception and had an accumulated deficit of $1.450B. Federal and state NOL carryforwards were approximately $1.1392B and $709.8M; a full $417.491M deferred-tax valuation allowance left net deferred tax assets at zero. Ownership-change limits may restrict use of NOLs and credits. The auditor issued unqualified opinions on the financial statements and internal control, while identifying point-in-time product revenue recognition as a critical audit matter because of the volume of transactions and systems involved.

Item 9B, Other Information

During the three months ended September 30, 2026, CFO Adam Laponis adopted a Rule 10b5-1 trading plan on August 5, allowing potential sales of up to 25,000 common shares and gifts of up to 1,500 shares. The plan expires on the earlier of November 19, 2027, or completion of all transactions.

Director Robert Chess adopted a Rule 10b5-1 plan on August 19, 2026, allowing potential sales of up to 25,588 common shares. It expires on the earlier of November 17, 2027, or the sale of all shares under the plan.

These plans describe potential transactions, not completed sales or gifts. No other directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter.

Feedback